Exclusive special offer and discount title banner vector image

SOUTH KOREA CANCER PAIN MANAGEMENT MARKET FORECAST 2024-2032

SCOPE OF THE REPORT

South Korea Cancer Pain Management Market by Drug Type (Opioids, Morphine, Non-opioids, Acetaminophen, Non-steroidal Anti-inflammatory Drugs, Nerve Blockers) Market by Disease Indication (Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Blood Cancer, Other Disease Indications)

REQUEST CUSTOMIZATION

MARKET OVERVIEW

The South Korea cancer pain management market is anticipated to develop with a CAGR of 5.92% during the forecast period 2024-2032. According to the Korean Cancer Association, an estimated 273,076 new cancer cases and 81,818 cancer deaths were expected in Korea in 2023. The most common cancer types include thyroid, lung, breast, rectum, colon, and stomach cancers, which together account for half of the overall cancer burden in the country. Lung cancer is anticipated to be the leading cause of cancer-related deaths, followed by liver, colorectal, pancreatic, and gallbladder cancers.

Growing cancer prevalence and enhanced government support for cancer care have significantly influenced the cancer pain management market in South Korea. Each year, between 10,000 and 20,000 individuals are diagnosed with cancer. Advances in diagnostic tools and pharmaceutical developments have increased the number of cancer survivors and improved their 5-year relative survival rates. This growing population of survivors underscores the need for effective pain management solutions to improve their quality of life.

South Korea Cancer Pain Management Market

To Know More About This Report, Request a Free Sample Copy

Additionally, South Korea is experiencing rapid population aging, with a significant increase in the number of elderly individuals. According to World Bank data, in 2022, the total population aged 65 and above was 9,030,344 in South Korea. As older adults are more susceptible to cancer, this demographic shift further drives the demand for comprehensive cancer pain management solutions. The rising incidence of cancer among the elderly necessitates specialized pain management approaches to meet their unique needs.

Innovations in palliative care are crucial to the cancer pain management market in South Korea. The development and implementation of advanced hospice palliative care (HPC) services, including policy changes that allow terminally ill patients to refuse life-sustaining treatments, highlight the country’s commitment to improving end-of-life care. These advancements in cancer treatment aim to enhance the quality of life for cancer patients by addressing their physical, emotional, and spiritual needs.

Need a custom report or have specific data requirements? Let us know!

The report on the South Korea cancer pain management market includes the segmentation analysis based on drug type and disease indication.

Market by Drug Type:

  • Opioids
  • Morphine
    • Fentanyl
    • Other Morphines
  • Non-Opioids
  • Acetaminophen
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
  • Nerve Blockers

Market by Disease Indication:

  • Lung Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Blood Cancer
  • Other Disease Indications

Inkwood Research’s report on the South Korea cancer pain management market provides in-depth insights as well as the market’s segmentation analysis. The detailed evaluation of the market includes Competitive Landscape and Value Chain Analysis. 

Key players operating in the South Korea cancer pain management market include Daiichi Sankyo Company Ltd, Pfizer, Teva Pharmaceutical Industries Limited, Mundipharma International, Hanmi Pharmaceutical Co, etc.

Teva Pharmaceutical Industries Limited, founded in 1901 and headquartered in Tel Aviv, Israel, is a global pharmaceutical company that produces a variety of medicines and biopharmaceutical products. The company specializes in cytotoxic substances, sterile products, hormones, and high-potency drugs. Teva offers medications in multiple forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It focuses on therapeutic areas such as respiratory, central nervous system (CNS), pain, and oncology. Teva operates in North America, Europe, Israel, and other international markets.

REPORT SYNOPSIS

REPORT SCOPEDETAILS
Market Forecast Years2024-2032
Base Year2023
Market Historical Years2018-2022
Forecast Units

Revenue ($ Million)

Segments Analyzed
Drug Type and Disease Indication
Countries AnalyzedSouth Korea
Companies AnalyzedDaiichi Sankyo Company Ltd, Pfizer, Teva Pharmaceutical Industries, Mundipharma International, Hanmi Pharmaceutical Co
TABLE OF CONTENTS
  1. RESEARCH SCOPE & METHODOLOGY
    1. STUDY OBJECTIVES
    2. METHODOLOGY
    3. ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    1. MARKET SIZE & ESTIMATES
    2. COUNTRY SNAPSHOT — SOUTH KOREA
    3. COUNTRY ANALYSIS — SOUTH KOREA
    4. SCOPE OF STUDY
    5. CRISIS SCENARIO ANALYSIS
      1. IMPACT OF COVID-19 ON THE SOUTH KOREA CANCER PAIN MANAGEMENT MARKET
    6. MAJOR MARKET FINDINGS
      1. INNOVATIONS IN PALLIATIVE CARE
      2. SURGE IN PERSONALIZED MEDICINE APPROACHES
      3. EXPANSION OF SPECIALIZED CANCER CARE FACILITIES
  3. MARKET DYNAMICS
    1. KEY DRIVERS
      1. INCREASING PREVALENCE OF CANCER IN SOUTH KOREA
      2. SURGE IN GERIATRIC POPULATION
      3. ADVANCED HEALTHCARE INFRASTRUCTURE
    2. KEY RESTRAINTS
      1. REGULATORY CHALLENGES AND APPROVAL DELAYS
      2. HIGH COST OF TREATMENT
      3. OPIOID SIDE EFFECTS AND ADDICTION CONCERNS
  4. KEY ANALYTICS
    1. KEY MARKET TRENDS
      1. ADVANCEMENTS IN MEDICAL TECHNOLOGY IN SOUTH KOREA
      2. SUPPORTIVE GOVERNMENT POLICIES FOR CANCER PAIN MANAGEMENT
      3. ACTIVE R&D BY PHARMACEUTICAL COMPANIES 
    2. PESTLE ANALYSIS
      1. POLITICAL
      2. ECONOMICAL
      3. SOCIAL
      4. TECHNOLOGICAL
      5. LEGAL
      6. ENVIRONMENTAL
    3. PORTER’S FIVE FORCES ANALYSIS
      1. BUYERS POWER
      2. SUPPLIERS POWER
      3. SUBSTITUTIONS
      4. NEW ENTRANTS
      5. INDUSTRY RIVALRY
    4. GROWTH PROSPECT MAPPING — SOUTH KOREA
    5. VALUE CHAIN ANALYSIS
      1. RESEARCH & DEVELOPMENT
      2. REGULATORY APPROVAL
      3. MANUFACTURING
      4. DISTRIBUTION
      5. END-USERS
  5. MARKET BY DRUG TYPE
    1. OPIOIDS
    2. MORPHINE
      1. FENTANYL
      2. OTHER MORPHINES
    3. NON-OPIOIDS
    4. ACETAMINOPHEN
    5. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
    6. NERVE BLOCKERS
  6. MARKET BY DISEASE INDICATION
    1. LUNG CANCER
    2. COLORECTAL CANCER
    3. BREAST CANCER
    4. PROSTATE CANCER
    5. BLOOD CANCER
    6. OTHER DISEASE INDICATIONS
  7. COMPETITIVE LANDSCAPE
    1. KEY STRATEGIC DEVELOPMENTS
      1. MERGERS & ACQUISITIONS
      2. PRODUCT LAUNCHES & DEVELOPMENTS
      3. PARTNERSHIPS & AGREEMENTS
      4. BUSINESS EXPANSIONS & DIVESTITURES
    2. COMPANY PROFILES
      1. DAIICHI SANKYO COMPANY LIMITED
        1. COMPANY OVERVIEW
        2. PRODUCTS
        3. STRENGTHS & CHALLENGES
      2. PFIZER
        1. COMPANY OVERVIEW
        2. PRODUCTS
        3. STRENGTHS & CHALLENGES
      3. TEVA PHARMACEUTICAL INDUSTRIES LIMITED
        1. COMPANY OVERVIEW
        2. PRODUCTS
        3. STRENGTHS & CHALLENGES
      4. MUNDIPHARMA INTERNATIONAL
        1. COMPANY OVERVIEW
        2. PRODUCTS
        3. STRENGTHS & CHALLENGES
      5. HANMI PHARMACEUTICAL CO
        1. COMPANY OVERVIEW
        2. PRODUCTS
        3. STRENGTHS & CHALLENGES

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT — CANCER PAIN MANAGEMENT

TABLE 2: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, BY DRUG TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 3: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, BY DRUG TYPE, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 4: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, BY MORPHINE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 5: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, BY MORPHINE, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 6: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, BY DISEASE INDICATION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 7: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, BY DISEASE INDICATION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 8: LIST OF MERGERS & ACQUISITIONS

TABLE 9: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

TABLE 10: LIST OF PARTNERSHIPS & AGREEMENTS

TABLE 11: LIST OF BUSINESS EXPANSIONS & DIVESTITURES

LIST OF FIGURES

FIGURE 1: KEY MARKET TRENDS

FIGURE 2: PORTER’S FIVE FORCES ANALYSIS

FIGURE 3: GROWTH PROSPECT MAPPING — SOUTH KOREA

FIGURE 4: VALUE CHAIN ANALYSIS

FIGURE 5: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, GROWTH POTENTIAL, BY DRUG TYPE, IN 2023

FIGURE 6: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, BY OPIOIDS, 2024-2032 (IN $ MILLION)

FIGURE 7: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, BY MORPHINE, 2024-2032 (IN $ MILLION)

FIGURE 8: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, GROWTH POTENTIAL, BY MORPHINE, IN 2023

FIGURE 9: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, BY FENTANYL, 2024-2032 (IN $ MILLION)

FIGURE 10: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, BY OTHER MORPHINES, 2024-2032 (IN $ MILLION)

FIGURE 11: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, BY NON-OPIOIDS, 2024-2032 (IN $ MILLION)

FIGURE 12: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, BY ACETAMINOPHEN, 2024-2032 (IN $ MILLION)

FIGURE 13: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2024-2032 (IN $ MILLION)

FIGURE 14: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, BY NERVE BLOCKERS, 2024-2032 (IN $ MILLION)

FIGURE 15: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, GROWTH POTENTIAL, BY DISEASE INDICATION, IN 2023

FIGURE 16: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, BY LUNG CANCER, 2024-2032 (IN $ MILLION)

FIGURE 17: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, BY COLORECTAL CANCER, 2024-2032 (IN $ MILLION)

FIGURE 18: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, BY BREAST CANCER, 2024-2032 (IN $ MILLION)

FIGURE 19: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, BY PROSTATE CANCER, 2024-2032 (IN $ MILLION)

FIGURE 20: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, BY BLOOD CANCER, 2024-2032 (IN $ MILLION)

FIGURE 21: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, BY OTHER DISEASE INDICATIONS, 2024-2032 (IN $ MILLION)

FAQ’s

Request Customization
Request Customization
Request Free Sample